Literature DB >> 28529901

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors.

Suchit H Patel1, Andreas Rimner1, Roger B Cohen2.   

Abstract

Recent work with immunotherapy has shown promising results with treatment of several solid malignancies, and there are several reports of good systemic responses with the combination of immunotherapy and radiation therapy (RT), most notably in advanced melanoma. Given the rapid increase in the use of checkpoint blockade as well as anti-tumor vaccines, we review here the preclinical rationale and ongoing clinical work in combining immunotherapy with RT for small cell lung cancer (SCLC) and thymic tumors. While there are several reports of promising results with the combination of immunotherapy and conventional systemic treatment, we focus here on the ongoing clinical studies that combine immunotherapy with RT, and highlight the emerging data for this multimodality approach as well as key preclinical and clinical issues that remain to be addressed. With regards to SCLC, trials exploring to the combination of immunotherapy and RT are already ongoing, but clinical studies for this combination in thymoma are lacking.

Entities:  

Keywords:  Immunotherapy; radiation; small cell lung cancer (SCLC); thymoma

Year:  2017        PMID: 28529901      PMCID: PMC5420531          DOI: 10.21037/tlcr.2017.03.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  79 in total

1.  Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.

Authors:  P Maddison; J Newsom-Davis; K R Mills; R L Souhami
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

Review 2.  The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.

Authors:  Leora Horn; Martin Reck; David R Spigel
Journal:  Oncologist       Date:  2016-06-27

3.  Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

Authors:  Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Reidulv Hatlevoll; Ragnar Dahle; Nils Boye; Mari Wang; Tor Vigander; Jan Vilsvik; Eva Skovlund; Einar Hannisdal; Steinar Aamdal
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

5.  Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retrospective Multicenter Study.

Authors:  Ankit Modh; Andreas Rimner; Pamela K Allen; Brad Greenfield; Edith M Marom; David Rice; James Huang; Kenneth E Rosenzweig; Ritsuko Komaki; Daniel R Gomez
Journal:  Am J Clin Oncol       Date:  2016-04       Impact factor: 2.339

6.  Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Martin Reck; Alexander Luft; Aleksandra Szczesna; Libor Havel; Sang-We Kim; Wallace Akerley; Maria Catherine Pietanza; Yi-Long Wu; Christoph Zielinski; Michael Thomas; Enriqueta Felip; Kathryn Gold; Leora Horn; Joachim Aerts; Kazuhiko Nakagawa; Paul Lorigan; Anne Pieters; Teresa Kong Sanchez; Justin Fairchild; David Spigel
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

7.  ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.

Authors:  Alexander Marx; Philipp Ströbel; Sunil S Badve; Lara Chalabreysse; John K C Chan; Gang Chen; Laurence de Leval; Frank Detterbeck; Nicolas Girard; Jim Huang; Michael O Kurrer; Libero Lauriola; Mirella Marino; Yoshihiro Matsuno; Thierry Jo Molina; Kiyoshi Mukai; Andrew G Nicholson; Daisuke Nonaka; Ralf Rieker; Juan Rosai; Enrico Ruffini; William D Travis
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 9.  Thymoma: current diagnosis and treatment.

Authors:  Frank C Detterbeck; Ahmad Zeeshan
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

10.  Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.

Authors:  I Petrini; P S Meltzer; P A Zucali; J Luo; C Lee; A Santoro; H S Lee; K J Killian; Y Wang; M Tsokos; M Roncalli; S M Steinberg; Y Wang; G Giaccone
Journal:  Cell Death Dis       Date:  2012-07-19       Impact factor: 8.469

View more
  5 in total

Review 1.  Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.

Authors:  Yan Ting Shue; Jing Shan Lim; Julien Sage
Journal:  Transl Lung Cancer Res       Date:  2018-02

2.  Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.

Authors:  Feliciano Barrón; Roberto Sánchez; Marisol Arroyo-Hernández; Carolina Blanco; Zyanya L Zatarain-Barrón; Rodrigo Catalán; Maritza Ramos-Ramírez; Andrés F Cardona; Diana Flores-Estrada; Oscar Arrieta
Journal:  Front Oncol       Date:  2020-09-29       Impact factor: 6.244

3.  Establishing CD19 B-cell reference control materials for comparable and quantitative cytometric expression analysis.

Authors:  Lili Wang; Rukmini Bhardwaj; Howard Mostowski; Paul N Patrone; Anthony J Kearsley; Jessica Watson; Liang Lim; Jothir Pichaandi; Olga Ornatsky; Daniel Majonis; Steven R Bauer; Heba A Degheidy
Journal:  PLoS One       Date:  2021-03-19       Impact factor: 3.240

4.  A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada.

Authors:  Anifat A Elegbede; Amanda J Gibson; Andrea S Fung; Winson Y Cheung; Michelle L Dean; D Gwyn Bebb; Aliyah Pabani
Journal:  JTO Clin Res Rep       Date:  2021-10-28

5.  Studying the Anticancer Effects of Thymoquinone on Breast Cancer Cells through Natural Killer Cell Activity.

Authors:  Huda F Alshaibi; Nouf A Aldarmahi; Nuha A Alkhattabi; Hadeil M Alsufiani; Nesrin I Tarbiah
Journal:  Biomed Res Int       Date:  2022-09-20       Impact factor: 3.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.